New drug trial aims to reverse devastating muscle wasting in cancer

NCT ID NCT07168226

Summary

This study is testing an investigational drug called ASCA101 to see if it can help cancer patients with cachexia, a severe condition causing weight loss and muscle wasting. About 135 adults with certain solid tumors who have lost significant weight will receive either ASCA101, an existing treatment, or a placebo for 12 weeks. Researchers will measure changes in body weight, muscle mass, strength, and appetite to see if the new treatment is safe and effective.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CACHEXIA; CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ajou University Hospital

    Gyeonggi-do, Suwon-si, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Chung-Ang University Gwangmyeong Hospital

    Gyeonggi-do, Gwangmyeong-si, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Korea University Anam Hospital

    Seoul, Seongbuk-gu, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • National Cancer Center

    Gyeonggi-do, Goyang-si, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Samsung Medical Center

    Seoul, Gangnam-gu, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Seoul ST. Mary's hospital

    Seoul, Seocho-gu, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.